Press releases
ROME Therapeutics Announces Publication in Nature Communications of First Large-Scale, Pan-Cancer Analysis of LINE-1 Expression Levels and Retrotransposon Activity
ROME Therapeutics Debuts First Preclinical Data of its LINE-1 Reverse Transcriptase (RT) Inhibitors in Neurodegenerative Diseases at 3rd Annual Dark Genome Symposium
ROME Therapeutics to Present Data Supporting LINE-1 Reverse Transcriptase Inhibitors as a Novel Treatment for Autoimmune Diseases at ACR Convergence 2024
ROME Therapeutics, Enara Bio, Nucleome Therapeutics and NYU Langone Health to Host 3rd Annual Dark Genome Symposium
ROME Therapeutics to Participate in 2024 Cantor Global Healthcare Conference
ROME Therapeutics to Participate in 2024 Wedbush PacGrow Healthcare Conference
ROME Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
ROME Therapeutics Appoints Heike Keilhack, Ph.D., as Chief Scientific Officer
ROME Publishes Landmark Nature Paper Revealing First High-Resolution Structure of LINE-1 Reverse Transcriptase (RT) for Drug Discovery
ROME Therapeutics Presents First Data to Validate LINE-1 RT as a Novel Target in Autoimmune Diseases and the Therapeutic Potential of its First-in-Class LINE-1 RT Inhibitors
Enara Bio, ROME Therapeutics and Nucleome Therapeutics to Host 2nd Annual Dark Genome Symposium
ROME Expands Leadership Team with the Appointment of Industry Veteran Kyle Kuvalanka as Chief Financial Officer and Chief Business Officer
ROME Therapeutics Closes Oversubscribed $72 Million Series B Extension to Support Advancement of Lead Program into Clinical Development for Autoimmune Disease
ROME Therapeutics Appoints Keith Wilcoxen, Ph.D., as Executive Vice President, Early Development
ROME Therapeutics Demonstrates Efficacy of its Novel LINE-1 Reverse Transcriptase Inhibitor in Translational Models of Autoimmune Disease
ROME Therapeutics and Enara Bio to Host Inaugural Dark Genome Symposium Convening Industry and Academic Leaders to Catalyze Therapeutic Application of Dark Genome Research
ROME Therapeutics Appoints Industry Veteran Jeff Hatfield as Chair of Board of Directors
ROME Therapeutics Announces Publication of First Crystal Structure of a Human Endogenous Reverse Transcriptase in PNAS
ROME Therapeutics Appoints Nurjana Bachman, Ph.D., as Senior Vice President, Corporate Development and Strategy
ROME Therapeutics Announces Preclinical Data Demonstrating Inhibition of Endogenous Reverse Transcriptase Activity Blocks Immune Response in Autoimmune Disease Models
ROME Therapeutics Secures $77 Million in Series B Financing to Advance Repeatome-derived Pipeline for Cancer and Autoimmune Diseases and Expand Repeatomics Platform
ROME Therapeutics Expands Science Leadership in Oncology, Data Science and New Target Discovery
ROME Therapeutics announces the appointment of Scott Biller, Ph.D. to its board.
ROME Therapeutics announces that it has been named by Fierce Biotech as one of 2020’s Fierce 15 biotechnology companies
ROME Therapeutics Appoints Drug Discovery Veteran Dennis Zaller, Ph.D., as Chief Scientific Officer
ROME Therapeutics Launches to Develop Novel Therapies for Cancer and Autoimmune Diseases by Harnessing the Power of the Repeatome
News and events
Risky Moves: Can blocking "jumping genes" treat diseases and aging? | Science
Startups probe hidden viruses in the 'dark genome' to treat disease | Nature Biotechnology
Unlocking the Dark Genome for Lupus and Other Autoimmune Diseases | Unseen Upside, a podcast by Cambridge Associates
Dark Genome Hunting with Rosana Kapeller and Marty Taylor | Raising Health™, a podcast by a16z Bio+Health
Enara Bio, ROME Therapeutics and Nucleome Therapeutics Host 2nd Annual Dark Genome Symposium
With latest fundraise, Rome Therapeutics works to drug the ‘dark genome’ | BioPharma Dive
Rome Therapeutics advances dark genome drug after completing $72M Series B extension backed by Big Pharma | Endpoints News
"Biotech in Boston" Event Featuring Rosana Kapeller, ROME CEO | Boston Business Journal
Rosana Kapeller Among "Disruptors" Featured on WMIF Panel | World Medical Innovation Forum
Panel: Maximizing Platform Potential, with ROME CSO Dennis Zaller | Longwood Healthcare Leaders Conference
BIO Panel on Oncology Drug Discovery Features ROME CSO Dennis Zaller | BIO International Convention
Panel: Building Strong Relationships with Boards and Investors, featuring Rosana Kapeller | Convergence Forum
Podcast: Harnessing the Power of the Repeatome with Dennis Zaller | Biotech2050 podcast
ROME honored in Endpoints 11: The top private biotechs in pursuit of new drugs | Endpoints News
The Mysterious Dark Genome: Panel Featuring Rosana Kapeller, CEO of ROME | World Medical Innovation Forum
The "Dark Genome" with Dr. Rosana Kapeller-Lieberman | GV "Theory and Practice" podcast
Kapeller's ROME bags $77M to strike gold in the backwaters of the genome | Fierce Biotech
Over 160 CEOs Sign MassBio’s Pledge to Create a More Equitable and Inclusive Life Sciences Industry | MassBio
ROME founder Rosana Kapeller recruits a CSO from the senior ranks of a major league R&D team | Endpoints News
Companies Strain to Outdo Each Other with Work-from-Home Perks (Think Ukuleles) | Wall Street Journal
From Rio to Rome: Rosanna Kapeller on The Long Run | The Timmerman Report
At ROME Therapeutics, Kapeller Aims to Turn “Junk” Into New Drugs | Xconomy
ROME Therapeutics launches to probe junk DNA for cancer drug discovery | C&EN
ROME Therapeutics debuts with $50M and Rosana Kapeller at the helm | Fierce Biotech
GV joins $50 million round in ROME Therapeutics to research ‘junk DNA’ for cancer therapies | VentureBeat
Nimbus founder Rosana Kapeller has a new company, with $50M and an eye on the ‘repeatome’ | Endpoints News
Scientific presentations
Exploring the therapeutic potential of LINE-1 RT inhibitors in Parkinson’s disease | Dark Genome Symposium 2024
Integrated structural biology of the LINE-1 retrotransposon | Dark Genome Symposium 2024
Novel LINE-1 Reverse Transcriptase Inhibitors Can Suppress Type I Interferon Responses and Are Promising Therapeutics for Lupus | ACR Convergence 2024
Highly repetitive elements hold promise as a rich source of cancer vaccine targets | SITC 2024
Repetitive element-derived neoantigens are a potential source of highly tumor-specific cancer vaccine targets | SITC 2024
LINE-1 produces cytosolic DNA products from self and non-self RNAs | CSHL Transposable Elements Conference 2024
Identifying novel regulators of LINE-1 expression through CRISPR/Cas9 screens | CSHL Transposable Elements Conference 2024
Elevated LINE-1 Expression in SLE Keratinocytes Leads to LINE-1 Reverse Transcriptase-dependent Type I Interferon Responses | ACR Convergence 2023
Mechanism-guided quantification of LINE-1 reveals p53 regulation of both retrotransposition and transcription | EMBO Workshop: The Mobile Genome
A Phase 0, single-center study to characterize the response of a UV-B skin challenge on the skin of healthy volunteers and cutaneous lupus erythematosus (CLE) patients | Dermatology Drug Development Summit 2023
High-resolution crystal structure of LINE-1 Reverse Transcriptase and Its Implications for Rational Inhibitor Design | Keystone Symposium 2023
Mechanism-guided quantification of LINE-1 reveals p53 regulation of both retrotransposition and transcription | bioRxiv
ROME Therapeutics company presentation | 41st J.P. Morgan Healthcare Conference
LINE1 Reverse Transcriptase Inhibitors Abrogate Type 1 Interferon Responses | American College of Rheumatology Convergence 2022
Human endogenous retrovirus-K (HERV-K) reverse transcriptase (RT) structure and biochemistry reveals remarkable similarities to HIV-1 RT and opportunities for HERV-K–specific inhibition | PNAS
Sensitive Detection of LINE-1 Retrotransposition Across Cancer Uncovers Biological Correlates | The Mobile DNA Conference: Evolution, Diversity, and Impact
Human endogenous retrovirus-K (HERV-K) reverse transcriptase (RT) displays a lamivudine resistant genotype and phenotype | 4th Symposium of the Canadian Society for Virology
Human endogenous retrovirus-k (HERV-K) reverse transcriptase (RT) forms an asymmetric homodimer reminiscent of HIV-1 RT | Cold Spring Harbor Laboratory: Fifty Years of Reverse Transcriptase
Reverse transcriptase inhibition disrupts repeat element life cycle in colorectal cancer | Cancer Discovery
Inhibitors of Endogenous Reverse Transcriptases Suppress in vitro Type I Interferon Responses and in vivo Antigen-specific T cell Responses | ACR Convergence 2021